Effect of Acute Exercise on Cognitive Functions and Blood Markers of Brain Plasticity in Regular Chronic Cannabis Users

NCT06081218 | Recruiting

• 1 other identifier: 2016_70
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Interestingly, exercise increase plasma AEA, one of the most famous endocannabinoid. This increase could be involved in exercise-induced neurogenesis and other beneficial exercise adaptations. Chronic cannabis use is associated with alteration of ECS activity. The aim of the study is to compare ECS response to exercise between chronic cannabis users and non-users.

Conditions

Cannabis User

Outcome Measures

Primary Outcomes (1)

• Plasma endocannabinoids levels (pmol/ml)

  2 weeks

Secondary Outcomes (5)

• regulating hormone of endocannabinoids (plasma levels of cortisol, ng/ml)

  2 weeks

• Blood marker of neurogenesis and neuroplasticity (plasma levels and BDNF, pg/ml)

  2 weeks

• change in cerebral muscular, oxygenation (HHB), (HbO2), (Hbtot) (arbitrary unit)

  2 weeks

• Cognitive function (selective attention, stroop test)

  2 weeks

• Oxygen consumption (VO2) (ml/min/kg)

  2 weeks

Study Arms (2)

Chronic cannabis users

EXPERIMENTAL

Other: activity test

Healthy subjects

SHAM COMPARATOR

Other: activity test

Interventions

activity test OTHER

Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power

Chronic cannabis users; Healthy subjects

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Cannabis consumer group:
• Cannabis consumption \> 100 times in lifetime, last exposure \< 7 days, and recent exposure \> 10 times in the month.
• Positive toxicological urine test for ∆-9-THC.
• Having a cannabis use disorder according to the CAST.
• Healthy group:
• Negative urine toxicological test for cannabis.
• No regular cannabis use for more than 6 months once in a lifetime.
• No cannabis consumption in the 6 months preceding the study.

You may not qualify if:

• For all subjects :
• Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs).
• Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit.
• Under medical treatment.
• Presence of diagnosed neurological disorders.
• Diagnosis of a psychotic picture entering axis I, DSM-5.
• Chronic progressive disease or in remission.
• Body mass index \> 30 kg/m2 (i.e. presence of obesity).

Sponsors & Collaborators

• University Hospital, Lille: lead

Study Sites (1)

CHU Lille

Lille, 59000, France

RECRUITING

MeSH Terms

Interventions

Carcinogenicity Tests

Intervention Hierarchy (Ancestors)

Toxicity Tests; Investigative Techniques

Central Study Contacts

Olivier Cottencin, MD,PhD

CONTACT

0320445962; olivier.cottencin@chru-lille.fr

Francois-xavier Gamelin, PhD

CONTACT

06.26.19.23.09; francois-xavier.gamelin@univ-lille.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2023
• First Posted: October 13, 2023
• Study Start: May 7, 2024
• Primary Completion (Estimated): May 31, 2029
• Study Completion (Estimated): December 31, 2029
• Last Updated: May 13, 2025

Record last verified: 2025-01

Locations

FR (1)